Aldeyra Therapeu (NQ: ALDX )

13.37 USD +1.18 (+9.68%)

Official Closing Price Updated: 6:55 PM EST, Jan 15, 2021 Add to My Watchlist

Price and Volume

Volume	3,351,100
Open	12.35
Bid (Size)	12.90 (2)
Ask (Size)	13.31 (10)
Prev. Close	12.19
Today's Range	12.31 - 13.60
52wk Range	1.480 - 13.60
Shares Outstanding	20,109,394
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

January 13, 2021

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with...

Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

January 13, 2021

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with...

Performance

YTD	+104.75%	+104.75%
1 Month	+77.56%	+77.56%
3 Month	+68.18%	+68.18%
6 Month	+104.75%	+104.75%
1 Year	+113.58%	+113.58%

More News

Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity

January 16, 2021

Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference

January 08, 2021

Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

January 07, 2021

3 Biotech Stocks That Jumped Last Week

Today 9:59 EST

Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer’s Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial

January 06, 2021

Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity

January 16, 2021

Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612

December 22, 2020

Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis

December 17, 2020

Why Aldeyra Therapeutics Stock Is Jumping Today

January 14, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.